Disease Segment Analysis: Dyspareunia (Largest Segment) vs Hypoactive Sexual Desire Disorder (HSDD) (Fastest-Growing Segment)

The dyspareunia segment dominated the female sexual dysfunction treatment market, accounting for 48.02% of the market share in 2026. The high prevalence of pain-related sexual disorders and the increasing willingness of women to seek medical evaluation have contributed significantly to the segment's leadership. Improvements in clinical awareness, better diagnostic practices, and the availability of multiple therapeutic approaches have supported greater treatment uptake. Growing emphasis on women's sexual health and quality of life has further reinforced demand for effective dyspareunia management.

The hypoactive sexual desire disorder (HSDD) segment is anticipated to witness the fastest growth as awareness of female sexual wellness continues to expand and healthcare providers increasingly recognize HSDD as a treatable medical condition. Ongoing advances in therapeutic options, improved patient education, and broader discussions surrounding women's health are encouraging earlier diagnosis and intervention. Greater acceptance of seeking treatment for sexual health concerns is expected to sustain the segment's rapid expansion.

Route of Administration Segment Analysis: Parenteral (Largest Segment) vs Topical (Fastest-Growing Segment)

Holding the largest share of the female sexual dysfunction treatment market, the parenteral segment accounted for 41.47% of the market share in 2026. Parenteral therapies are widely utilized when precise dosing, rapid therapeutic action, and improved bioavailability are required for specific treatment regimens. Their use in clinically supervised settings and established treatment protocols has supported continued adoption, particularly for patients requiring specialized care.

The topical segment is expected to register the fastest growth due to increasing patient preference for localized, non-invasive treatment approaches that offer convenience and ease of administration. Topical formulations may help reduce systemic exposure while improving patient adherence, making them an attractive option for long-term management. Continued product innovation and growing demand for personalized treatment strategies are expected to accelerate adoption of topical therapies.

Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Online Pharmacies (Fastest-Growing Segment)

The hospital pharmacies segment led the female sexual dysfunction treatment market, capturing 50.77% of the market share in 2026. Hospital pharmacies play an important role in dispensing prescription therapies under medical supervision while ensuring appropriate patient counseling and treatment monitoring. Their integration with specialized healthcare services and access to prescription medications have reinforced the segment's dominant position.

The online pharmacies segment is projected to experience the fastest growth as digital healthcare platforms continue to expand and consumers increasingly value convenient access to prescribed treatments. Home delivery services, greater privacy during the purchasing process, and the growing adoption of telemedicine are encouraging more patients to obtain therapies through online channels. These trends are expected to strengthen the role of online pharmacies in the distribution landscape.